Antibody Discovery News and Research

RSS

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS Limited, a leader in antibody discovery and optimization of human monoclonal antibody libraries, today announced an agreement with Teva Pharmaceuticals (Teva) to apply its technologies and know-how to the optimization of human antibodies for use as biotherapeutics.

From FairJourney Biologics 31 Jul 2019

NIAID awards $22 million grant to develop antibody-based therapies against lethal viruses

The National Institute of Allergy and Infectious Diseases has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.

4 Apr 2019

IONTAS wins 'Small Business of the Year' category at Cambridge News Business Excellence Awards 2019

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has won ‘Small Business of the Year’ category at the Cambridge News Business Excellence Awards 2019.

25 Mar 2019

AvantGen and ACROBiosystems sign vendor agreement

AvantGen Inc., a world-leading CRO for human and rabbit antibody discovery and optimization, and ACROBiosystems Inc., a global biotech company specializing in recombinant protein technology jointly announced the signing of a preferred vendor agreement between the parties.

From ACROBiosystems 7 Mar 2019

Sphere Fluidics announces closure of $2 million (circa £1.5 million) investment round

Sphere Fluidics announced today that is has closed a $2 million (circa £1.5 million) investment round.

From Society for Laboratory Automation and Screening (SLAS) 30 Jan 2019

Sphere Fluidics and PAA collaborate to offer automated micro-plate handling capabilities for single cell analysis

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation, a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis.

30 Jan 2019

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

Dr. John McCafferty celebrates the success of phage display technology with Nobel Prize in Chemistry Laureates.

From FairJourney Biologics 12 Dec 2018

Integral Molecular and Merus collaborate to develop bispecific antibody therapeutics

Integral Molecular, the industry leader in the discovery of monoclonal antibodies against membrane proteins, and Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced that they have entered into a collaboration on multiple undisclosed targets.

12 Dec 2018

Vanderbilt researchers isolate antibody that can neutralize West Nile virus

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can "neutralize" the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

21 Nov 2018

Antibody Screening Tools; Improving Workflows

Antibody screening tools have exponentially increased the rate that candidates can be screened, multiplexing will increase processing to thousands per hour.¬

From Sartorius 9 Oct 2018

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.

20 Aug 2018

IONTAS collaborates with LG Chem to discover antibodies for treating cancer

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, today announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers.

5 Jun 2018

Oxford University Press and Chinese Antibody Society partner to launch Antibody Therapeutics

Oxford University Press and the Chinese Antibody Society are pleased to announce their new partnership to launch the journal Antibody Therapeutics this spring.

9 May 2018

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

20 Feb 2018

New findings could lead to first broadly effective ebolavirus therapies and vaccines

After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.

19 May 2017

Sartorius to Acquire Real-Time Live-Cell Analysis Pioneer and Leader Essen BioScience

Sartorius, a leading partner to the biopharmaceutical industry and laboratories, today signed an agreement to acquire U.S. based Essen BioScience Inc.,

From Sartorius 6 Mar 2017

Researchers identify new group of powerful Ebola-fighting antibodies

A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus.

22 Feb 2016

MD Anderson signs collaborative research and development agreement with Enumeral

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.

12 Jan 2016

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

AnaptysBio announces completion of oversubscribed $40MM Series D financing round

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an oversubscribed $40MM Series D financing round.

15 Jul 2015